Medtronic (MDT) Stock Price, News & Analysis

-0.91 (-1.12%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
5.03 million shs
Average Volume
6.27 million shs
Market Capitalization
$106.73 billion
P/E Ratio
Dividend Yield
Price Target

Medtronic MarketRank™ Stock Analysis

Analyst Rating
2.40 Rating Score
18.1% Upside
$94.91 Price Target
Short Interest
0.93% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.79mentions of Medtronic in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$2.68 M Sold Last Quarter
Proj. Earnings Growth
From $5.20 to $5.46 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.60 out of 5 stars

Medical Sector

67th out of 909 stocks

Electromedical Equipment Industry

2nd out of 18 stocks

MDT stock logo

About Medtronic Stock (NYSE:MDT)

Medtronic PLC is a world-leading medical technology company that develops and manufactures device-based medical therapies to improve patient outcomes. Founded in 1949 in Minneapolis, Minnesota, Medtronic has grown to become one of the largest medical device companies in the world. The company's operational and executive headquarters are in Dublin, Ireland, with over 90,000 employees in more than 150 countries.

Medtronic's portfolio of medical technologies includes products for diagnosing, treating and managing cardiac rhythm disorders and cardiovascular disease, spinal and biologics, diabetes management and neuromodulation. The company's cardiac and vascular group is the oldest and largest business unit, which develops pacemakers, defibrillators and heart valves. Medtronic's spinal and biologics business is the second-largest business unit and produces a range of implants, instruments and services to treat spinal disorders. The diabetes group develops insulin pumps, continuous glucose monitoring systems and consumables. At the same time, the neuromodulation business focuses on therapies to treat chronic pain, movement disorders and other neurological conditions.

In 2015, Medtronic acquired Covidien PLC, an Irish-based medical technology company, and moved its legal headquarters to Ireland. This transaction was the most significant U.S. corporate tax inversion in history and allowed the company to take advantage of lower corporate taxes in Ireland. The company also achieved a 100% gender and ethnically diverse pay equity in the U.S. and 99% gender pay equity globally, as reported in its Global Inclusion, Diversity and Equity 2022 annual report. Medtronic joined the Bloomberg Gender-Equality Index (GEI) in 2023, becoming one of the 483 companies listed in the index. 

Medtronic's stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol MDT and is a member of the S&P 500 and the Dow Jones Industrial Average (DJIA). The company has had several recent recalls, including the HeartWare Ventricular Assist Device in February 2021 and the controller ports in June 2021. 

Medtronic has continued to focus on developing its medical technology portfolio and announced several acquisitions and partnerships in 2021. In January, the company announced its intention to acquire Affera, Inc., Stimgenics LLC and Medicrea. In May, Medtronic announced a strategic partnership with CathWorks, and in March 2022, a contract with Vizient. The company is also working with GE Healthcare to support the needs and care demands at Ambulatory Surgery Centers in April 2022. In October 2022, Medtronic announced its intention to pursue a separation of the company's combined patient monitoring and respiratory interventions businesses. 

Medtronic PLC is a world-leading medical technology company that has grown to become one of the largest medical device companies in the world. With its portfolio of medical technologies and recent acquisitions and partnerships, the company is well-positioned to capitalize on the growth of the medical device industry. The company's commitment to gender and ethnic pay equity and inclusion and its strategic partnerships and acquisitions make Medtronic PLC an attractive option for investors looking for a long-term growth opportunity.

MDT Stock Price History

MDT Stock News Headlines

Intuitive Surgical Leads the Robotic Surgery Movement (MDT)
Intuitive Surgical is the pioneer in robotic-assisted surgery, investors hope the fifth generation of its da Vinci system can push ISRG stock higher
Medtronic plc (NYSE:MDT) EVP Sells $71,001.56 in Stock
Pentagon contract could send this $2 AI stock soaring
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...
DexCom Stock Gains from GLP-1 Diabetic Users (MDT)
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
Medtronic (NYSE:MDT) Stock Price Up 0.4%
Looking Into Medtronic's Recent Short Interest
Pentagon contract could send this $2 AI stock soaring
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...
Medtronic Stock: Buy, Sell, or Hold?
Medtronic: Dividend Aristocrat Value In Plain Sight
See More Headlines
Receive MDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medtronic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 4/12 Dividend
Dividend Payable
Fiscal Year End
Next Earnings (Confirmed)

Industry, Sector and Symbol

Electromedical equipment
Health Care Equipment
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$3.76 billion
Pretax Margin


Sales & Book Value

Annual Sales
$31.23 billion
Cash Flow
$7.31 per share
Book Value
$38.83 per share


Outstanding Shares
Free Float
Market Cap
$106.77 billion

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Geoffrey Straub Martha (Age 54)
    Chairman of the Board & CEO
    Comp: $1.79M
  • Ms. Karen L. ParkhillMs. Karen L. Parkhill (Age 59)
    Executive VP & CFO
    Comp: $992.24k
  • Mr. Sean M. SalmonMr. Sean M. Salmon (Age 59)
    Executive VP & President of Cardiovascular Portfolio
    Comp: $900.97k
  • Mr. Robert J. W. ten Hoedt (Age 64)
    Executive VP & President of Global Regions
    Comp: $1.24M
  • Mr. Mark Ploof
    Senior Vice President of Global Operations and Business Services
  • Ms. Jennifer M. Kirk (Age 49)
    Senior VP, Global Controller & Chief Accounting Officer
  • Dr. Kenneth E. Washington Ph.D. (Age 64)
    Senior VP and Chief Technology & Innovation Officer
  • Dr. Laura Mauri M.D.
    M.Sc., Senior VP and Chief Scientific, Medical & Regulatory Officer
  • Mr. Ryan Weispfenning
    VP & Head of Investor Relations
  • Mr. Ivan K. Fong (Age 63)
    Executive VP, General Counsel & Secretary
    Comp: $985.57k

Should I Buy Medtronic Stock? MDT Pros and Cons Explained


Here are some ways that investors could benefit from investing in Medtronic plc:

  • Medtronic plc has recently introduced innovative medical devices that are gaining market traction, potentially leading to increased revenue and market share.
  • The company's strong financial performance, including consistent revenue growth and profitability, indicates stability and potential for long-term returns.
  • Medtronic plc's stock price has shown resilience during market fluctuations, providing investors with a relatively stable investment option.
  • Continuous research and development efforts by Medtronic plc ensure a pipeline of new products, enhancing future growth prospects.
  • Expansion into emerging markets and strategic partnerships are opening up new revenue streams and diversifying the company's portfolio.


Investors should be bearish about investing in Medtronic plc for these reasons:

  • Regulatory challenges in the healthcare industry could impact Medtronic plc's product approvals and market access, leading to potential delays and uncertainties.
  • Intense competition in the medical device sector may put pressure on Medtronic plc's pricing and market share, affecting profitability.
  • Fluctuations in foreign exchange rates could impact Medtronic plc's international operations and financial performance, introducing currency risk to investors.
  • Dependency on a few key products for a significant portion of revenue exposes Medtronic plc to risks associated with product obsolescence or market shifts.
  • Economic downturns or healthcare policy changes could affect demand for Medtronic plc's products, impacting sales and profitability.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

MDT Stock Analysis - Frequently Asked Questions

Should I buy or sell Medtronic stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MDT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDT, but not buy additional shares or sell existing shares.
View MDT analyst ratings
or view top-rated stocks.

What is Medtronic's stock price target for 2024?

10 Wall Street analysts have issued 12-month price objectives for Medtronic's stock. Their MDT share price targets range from $82.00 to $106.00. On average, they predict the company's share price to reach $94.91 in the next year. This suggests a possible upside of 18.1% from the stock's current price.
View analysts price targets for MDT
or view top-rated stocks among Wall Street analysts.

How have MDT shares performed in 2024?

Medtronic's stock was trading at $82.38 at the beginning of 2024. Since then, MDT stock has decreased by 2.5% and is now trading at $80.33.
View the best growth stocks for 2024 here

Are investors shorting Medtronic?

Medtronic saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 11,530,000 shares, an increase of 36.4% from the February 29th total of 8,450,000 shares. Based on an average trading volume of 6,070,000 shares, the short-interest ratio is currently 1.9 days. Currently, 0.9% of the shares of the company are short sold.
View Medtronic's Short Interest

When is Medtronic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our MDT earnings forecast

How were Medtronic's earnings last quarter?

Medtronic plc (NYSE:MDT) released its quarterly earnings data on Tuesday, February, 20th. The medical technology company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.26 by $0.04. The medical technology company had revenue of $8.09 billion for the quarter, compared to the consensus estimate of $7.95 billion. Medtronic had a trailing twelve-month return on equity of 13.71% and a net margin of 13.00%. The firm's revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $1.30 EPS.
Read the conference call transcript

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Thursday, March 7th. Stockholders of record on Friday, March 22nd will be paid a dividend of $0.69 per share on Friday, April 12th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend is Thursday, March 21st.
Read our dividend analysis for MDT

Is Medtronic a good dividend stock?

Medtronic (NYSE:MDT) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.43%. The company has been increasing its dividend for 47 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 87.90%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MDT will have a dividend payout ratio of 50.55% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MDT.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of 5.190-5.210 for the period, compared to the consensus estimate of 5.160. The company issued revenue guidance of $32.1 billion-$32.3 billion, compared to the consensus revenue estimate of $32.1 billion.

What is Omar S. Ishrak's approval rating as Medtronic's CEO?

1,925 employees have rated Medtronic Chief Executive Officer Omar S. Ishrak on Glassdoor.com. Omar S. Ishrak has an approval rating of 92% among the company's employees. This puts Omar S. Ishrak in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS), Home Depot (HD) and Walmart (WMT).

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a number of retail and institutional investors. Top institutional investors include Raymond James & Associates (0.45%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Raymond James Financial Services Advisors Inc. (0.21%), Saratoga Research & Investment Management (0.10%), Allspring Global Investments Holdings LLC (0.07%) and Miller Howard Investments Inc. NY (0.05%). Insiders that own company stock include Bradley E Lerman, Brett A Wall, Brett A Wall, Carol A Surface, Geoffrey Martha, Gregory L Smith, Hoedt Rob Ten, John R Liddicoat, Karen L Parkhill, Karen L Parkhill, Michael Marinaro, Richard H Anderson, Robert John White and Sean Salmon.
View institutional ownership trends

How do I buy shares of Medtronic?

Shares of MDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:MDT) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners